Micrographia Bio
Micrographia aims to transform drug discovery by resolving the true molecular functions of potential therapeutics at scale.
The current drug discovery paradigm for new human medicines is painful, expensive and slow. One of the under-recognized reasons for the dismal clinical success rate is that scientists often do not understand exactly how a drug actually works (its mechanism of action) prior to entering into human clinical trials.
Micrographia Bio has developed a new approach which uses spatial proteomics for assessment of the true mechanism of action of drug candidates. Through understanding the true inner-workings of drug candidates, MGB aims to have an increased advantage for clinical success.
Founders
Julia Fan Li
CEO
Julia completed a PhD Engineering which focused on innovative financing solutions for global health. Stemming from her PhD research at Gates Cambridge, she originated, raised and deployed the world’s first $108 Million Global Health Investment Fund with Lion’s Head Global Partners and the Bill and Melinda Gates Foundation.
Christopher Thompson
CTO
Christopher originally attended the University of Louisville and achieved a Masters in Microbiology. He went on to take a PhD at Imperial College London in Microbial Pathogenesis. He stayed in academia studying cancer research before joining a startup as an ML engineer.
Milestones
Founded at Entrepreneur First
Seed ($2.1 Million)
Seed extension ($5.5 Million)